Home/Filings/4/0001227556-25-000007
4//SEC Filing

LIPPS RANDALL A 4

Accession 0001227556-25-000007

CIK 0000926326other

Filed

Dec 2, 7:00 PM ET

Accepted

Dec 3, 4:05 PM ET

Size

11.0 KB

Accession

0001227556-25-000007

Insider Transaction Report

Form 4
Period: 2025-12-01
LIPPS RANDALL A
DirectorPresident and CEO
Transactions
  • Exercise/Conversion

    Common Stock

    2025-12-01$27.70/sh+28,250$782,525414,898 total
  • Sale

    Common Stock

    2025-12-01$35.97/sh28,250$1,016,093386,648 total
  • Exercise/Conversion

    Stock Option NQ (Right to Buy)

    2025-12-0128,2500 total
    Exercise: $27.70Exp: 2026-02-04Common Stock (28,250 underlying)
Holdings
  • Common Stock

    (indirect: By Trust)
    355,861
  • Common Stock

    (indirect: By Trust)
    8,051
Footnotes (5)
  • [F1]This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2025.
  • [F2]The price reported in Column 4 is a weighted average price of $35.9679. The sold price range between $35.65 to $36.4746. The reporting person undertakes to provide to Omnicell, Inc., any security holder of Omnicell, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • [F3]Shares held in trust with Mr. Lipps' wife.
  • [F4]Shares held in trust for the benefit of Mr. Lipps' children.
  • [F5]The options were granted on 2/4/2016 with 25% vested on the one-year anniversary of the grant date and the reaming amount vesting ratably over a 36 month period. The options were fully vested on 2/4/2020.

Issuer

OMNICELL, INC.

CIK 0000926326

Entity typeother

Related Parties

1
  • filerCIK 0001227556

Filing Metadata

Form type
4
Filed
Dec 2, 7:00 PM ET
Accepted
Dec 3, 4:05 PM ET
Size
11.0 KB